GenPhar, Inc. - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 29

GenPhar, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “GenPhar, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- GenPhar, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of GenPhar, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of GenPhar, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the GenPhar, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate GenPhar, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of GenPhar, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the GenPhar, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with GenPhar, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of GenPhar, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
GenPhar, Inc. Snapshot
GenPhar, Inc. Overview
Key Information
Key Facts
GenPhar, Inc. – Research and Development Overview
Key Therapeutic Areas
GenPhar, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
GenPhar, Inc. – Pipeline Products Glance
GenPhar, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
GenPhar, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
GenPhar, Inc. – Drug Profiles
Drug For Dengue Virus
Product Description
Mechanism of Action
R&D Progress
TheraVax Based Hepatitis B Vaccine
Product Description
Mechanism of Action
R&D Progress
Dengue Virus Vaccine
Product Description
Mechanism of Action
R&D Progress
Ebola Virus Vaccine
Product Description
Mechanism of Action
R&D Progress
HIV Vaccine
Product Description
Mechanism of Action
R&D Progress
Marburg Virus Vaccine
Product Description
Mechanism of Action
R&D Progress
SARS Vaccine
Product Description
Mechanism of Action
R&D Progress
TheraVax Based Hepatitis C Vaccine
Product Description
Mechanism of Action
R&D Progress
West Nile Virus Vaccine
Product Description
Mechanism of Action
R&D Progress
GenPhar, Inc. – Pipeline Analysis
GenPhar, Inc. – Pipeline Products by Therapeutic Class
GenPhar, Inc. Pipeline Products By Target
GenPhar, Inc. – Pipeline Products by Molecule Type
GenPhar, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 04, 2008: US Army Medical Research Institute Of Infectious Diseases (USAMRIID) To Publish The Success Of Marburg Virus Vaccine Developed With GenPhar, Inc.
Mar 04, 2008: Congress Has Approved $3 Million To Supplement GenPhar And U.S. Navy Collaboration On Developing Multivalent Dengue Vaccine
Nov 09, 2006: GenPhar's Dengue Vaccine Demonstrates 100% Efficacy And Safety
Oct 07, 2002: GenPhar's Vaccine Platform Yields Promising Results For Biowarfare Defense
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Private Tutoring - Global Strategic Business Report